Table 1 Patient and clinical characteristics for plasmacytoid urothelial carcinoma and urothelial carcinoma not otherwise specified cohorts.
All PUC | Up-front surgery PUC | NAC PUC | LA PUC | UC NOS | |
|---|---|---|---|---|---|
(N = 81) | (N = 29) | (N = 33) | (N = 18) | (N = 146) | |
Age | |||||
Median (range) | 65 (22–84) | 50 (43–84) | 59 (43–76) | 64 (22–84) | 65 (39–82) |
Sex | |||||
Male | 53 (65) | 19 (66) | 25 (76) | 8 (44) | 101 (46) |
Female | 28 (35) | 10 (35) | 8 (24) | 10 (56) | 45 (31) |
Clinical T stage | |||||
T2 | 57 (70) | 28 (97) | 23 (70) | 5 (27.8) | 67 (45.9) |
T3–4 | 24 (30) | 1 (3) | 10 (30) | 13 (72.2) | 79 (54.1) |
Clinical N stage | |||||
Negative | 73 (90) | 29 (100) | 33 (100) | 8 (44.4) | 146 (100) |
Positive | 8 (10) | 0 (0) | 0 (0) | 10 (55.6) | 0 (0) |
EUA findings | |||||
Normal | 50 (62) | 14 (48) | 30 (91) | 6 (33) | N/A |
LA/invasive | 12 (15) | 0 (0) | 0 (0) | 11 (61) | N/A |
ND/NP | 19 (24) | 15 (52) | 3 (9) | 1 (6) | N/A |
Preoperative chemotherapy | |||||
Yes | 51(63) | 0 (0) | 33 (100) | 18 (100) | 146 (100) |
No | 30 (37) | 29 (100) | 0 (0) | 0 (0) | 0 (0) |
Platinum type | |||||
Cisplatin based | 46 (90) | N/A | 33 (100) | 13 (72) | 146 (100) |
Carboplatin based | 5 (10) | N/A | 0 (0) | 5 (28) | 0 (0) |
Duration of systemic therapy | |||||
4 cycles | 29 (57) | N/A | 27 (82) | 2 (11) | 146 (100) |
>4 cycles | 22 (43) | N/A | 6 (18) | 16 (89) | 0 (0) |
